Hims & Hers Health (HIMS) AI Stock Analysis

Company Guidance

Management raised short‑term guidance and framed a growth + investment cadence: Q3 revenue is guided to $880–900M (+47–50% YoY) with adjusted EBITDA $75–95M (≈10% margin at midpoint), and full‑year 2026 revenue is now $3.1–3.3B (+32–41% YoY) with adjusted EBITDA $275–325M (≈9% margin at midpoint). They noted Q2 results of >$753M revenue (+~40% YoY) — $622M domestic (+16% YoY) and $131M international (>17x YoY, with Eucalyptus contributing ~ $40M) — adjusted EBITDA $60M (8% margin), GAAP net loss $86M, gross margin 64% (≈‑6 pts QoQ), operating cash flow of ‑$36M and free cash flow of ‑$68M in Q2 (>$260M operating cash flow over the last 12 months). Balance‑sheet actions include a $400M receivables facility, >$400M of convertible debt, >$840M cash & short‑term investments after a ~$225M upfront Eucalyptus payment, and $225M remaining on the buyback; international revenue is expected to be ≥$600M in 2026. Other measurable milestones cited: ~300k net new subscribers in Q2 (nearly 3M total), Hers on track for >$1B this year, five U.S. specialties >$100M annual run‑rate with testosterone becoming a sixth, U.K./Australia/Germany each >$100M annualized, AI pilot results showing 3x messaging, AI answering 80% of queries and ~50% reduction in nonclinical support tasks, and AI investments expected to pay back in 12–18 months, all underpinning the 2030 targets of ≥$6.5B revenue and $1.3B adjusted EBITDA.